Pomezia, Italy

Christopher Fincham


Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 1997-1998

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Christopher Fincham: Innovator in Pharmaceutical Chemistry

Introduction

Christopher Fincham is a notable inventor based in Pomezia, Italy. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of tachykinin antagonists. With a total of 3 patents to his name, Fincham's work has the potential to impact various therapeutic applications.

Latest Patents

Fincham's latest patents include innovative formulations and compositions related to tachykinins antagonists. The first patent refers to tachykinins antagonists of general formula (I), detailing their preparation and pharmaceutical compositions containing them. The second patent describes tachykinin receptor antagonists, also having general formula (I), along with their preparation and use in pharmaceutical formulations. These inventions highlight his expertise in creating effective pharmaceutical solutions.

Career Highlights

Christopher Fincham is currently employed at A. Menarini Industrie Farmaceutiche Riunite S.r.l., a prominent company in the pharmaceutical industry. His role at Menarini allows him to further his research and development efforts in creating innovative therapeutic agents.

Collaborations

Fincham has collaborated with notable colleagues, including Alessandro Sisto and Edoardo Potier. These partnerships have likely contributed to the advancement of his research and the successful development of his patents.

Conclusion

Christopher Fincham is a distinguished inventor whose work in pharmaceutical chemistry has led to valuable innovations in tachykinin antagonists. His contributions continue to shape the landscape of therapeutic development, showcasing the importance of collaboration and research in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…